Targeted therapy for anti-cancer drug resistance mediated by several kinase pathways activation
| Project/Area Number |
21590180
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Tokai University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
MACE Rothenberg L. Vanderbilt大学, 癌センター, 教授
YU Shyr Vanderbilt大学, 癌センター, 教授
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2009: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 癌 / 薬剤反応性 / 酵素 / シグナル伝達 / 核酸 |
|---|
| Research Abstract |
Idarubicin is one of the standard treatments for patients with acute myeloid leukemia. We have developed human acute leukemia cell line resistant to idarubucin. Several kinase pathways were activated in the resistant cell line. Small interfering RNA-mediated gene silencing of the activated kinases resulted in the partial reversal of drug resistance. The magnitude of reversal depended on the effectiveness of gene silencing. The resistance for idarubucin was also partially overcome by means of molecular targeted drugs or inhibitors that inhibit the activated kinases. The magnitude of reversal depended on the effectiveness of kinase inhibition.
|
Report
(4 results)
Research Products
(11 results)
